If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
== Uses == Whey is used to produce whey cheeses such as ricotta, Norwegian brunost, and whey butter and many other products for human consumption. The fat content of whey is low; 1,000 pounds of whey are required to make a few pounds of whey butter. It is also an additive in many processed foods, including breads, crackers, and commercial pastry, and in animal feed. Whey proteins consist primarily of α-lactalbumin and β-lactoglobulin. Sweet whey contains glycomacropeptide (GMP). It is also an abundant source of lactose which can further be used for the synthesis of lactose-based bioactive molecules. Dairy whey remaining from home-made cheesemaking has many uses. It is a dough conditioner and can be substituted for skimmed milk in most baked good recipes that require milk (bread, pancakes, muffins, etc.). Throughout history, whey was a popular drink in inns and coffee houses. When Joseph Priestley was at college at Daventry Academy, 1752–1755, he records that, on the morning of Wednesday, 22 May 1754, he "went with a large company to drink whey." This was probably "sack whey" or "wine whey". Whey is also one of the main ingredients of Rivella, a carbonated drink in Switzerland. In areas where cheese is made, excess whey byproduct is sometimes sprayed over hay fields as a fertilizer. Historically whey, being a byproduct of cheese making, was considered a waste product and was pumped into rivers and streams in the U.S. Since the whey contained protein, this practice led to the growth of large concentrations of algae.
While the nanomaterials themselves often cannot be eliminated or substituted with conventional materials, it may be possible to choose properties of the nanoparticle such as size, shape, functionalization, surface charge, solubility, agglomeration, and aggregation state to improve their toxicological properties while retaining the desired functionality. Handling procedures can also be improved, for example, using a nanomaterial slurry or suspension in a liquid solvent instead of a dry powder will reduce dust exposure. Engineering controls are physical changes to the workplace that isolate workers from hazards, mainly ventilation systems such as fume hoods, gloveboxes, biosafety cabinets, and vented balance enclosures. Administrative controls are changes to workers' behavior to mitigate a hazard, including training on best practices for safe handling, storage, and disposal of nanomaterials, proper awareness of hazards through labeling and warning signage, and encouraging a general safety culture. Personal protective equipment must be worn on the worker's body and is the least desirable option for controlling hazards. Personal protective equipment normally used for typical chemicals are also appropriate for nanomaterials, including long pants, long-sleeve shirts, and closed-toed shoes, and the use of safety gloves, goggles, and impervious laboratory coats. In some circumstances respirators may be used. Exposure assessment is a set of methods used to monitor contaminant release and exposures to workers.
=== Da–Di === Jeff Dahn (born 1957), Canadian materials chemist noted for significant contributions to lithium-ion batteries John Dalton (1766–1844), British chemist, physicist and meteorologist, whose work laid the foundations of modern atomic theory and stoichiometric chemistry Marie Maynard Daly (1921–2003), American biochemist who studied the chemistry of histones, protein synthesis, the relationships between cholesterol and hypertension, and uptake of creatine by muscle cells Carl Peter Henrik Dam (1895–1976), Danish biochemist, winner of the 1943 Nobel Prize in Physiology or Medicine for discovering vitamin K and its role in human physiology Samuel J. Danishefsky (born 1936), American organic chemist, natural product total synthesis, 1995/6 Wolf Prize in Chemistry Raymond Davis, Jr.
Sources: en.wikipedia.org
=== Myopathies with central nuclei === Myopathies with central nuclei, such as myotubular myopathy, involves an error in the gene involved in vesicle movement throughout the cell. This creates problems in vesicles reaching the plasma membrane with the cellular components necessary to fuse myoblast, a major step in the formation of the skeletal muscle. This creates structural problems throughout the skeletal muscle and in the Z line of the sarcomere, creating the weakness in the muscle.
The general justifications for limiting free movement in TFEU article 45(3) are "public policy, public security or public health", and there is also a general exception in article 45(4) for "employment in the public service".
== Diagnosis == While heterotopic bone growth can begin spontaneously in FOP patients, Eastlack, like most patients, first experienced a triggered proliferation due to an illness or injury. When he was three or four years old, in 1937, while playing with his sister Helene, on a local street, a car hit him and injured his leg. He was taken to the hospital where his leg was put in a cast before returning home. The fracture never set properly, and when the cast was removed months later, his leg was painfully swollen with a high amount of inflammation. No further action was taken and shortly after, Eastlack began to experience his first set of abnormal bone growths. His hips and knees had become difficult to move. When he was taken to the hospital with this concern, the doctor took X-rays in which the bony deposits on his thigh muscles were revealed. The doctors were not able to diagnose his condition having seen this, and it continued to progress in the anatomically characteristic manner that FOP does. Eastlack soon suffered flare-ups along his back, neck, and chest. In attempts to diagnose and treat Eastlack's condition, the doctors ordered biopsies and performed a total of 11 surgical procedures to remove excess and heterotopic ossification, such as that on his thigh muscles. However, Eastlack's condition was aggravated by such procedures and the bone plates returned thicker and more predominant. It was 1938, the year after the incident, when he was finally diagnosed with myositis ossificans progressiva, which is now known as fibrodysplasia ossificans progressiva (FOP).
PAHs, subjected to interstellar medium (ISM) conditions, are transformed, through hydrogenation, oxygenation, and hydroxylation, to more complex organic compounds—"a step along the path toward amino acids and nucleotides, the raw materials of proteins and DNA, respectively". Further, as a result of these transformations, the PAHs lose their spectroscopic signature which could be one of the reasons "for the lack of PAH detection in interstellar ice grains, particularly the outer regions of cold, dense clouds or the upper molecular layers of protoplanetary disks." Low-temperature chemical pathways from simple organic compounds to complex PAHs are of interest. Such chemical pathways may help explain the presence of PAHs in the low-temperature atmosphere of Saturn's moon Titan, and may be significant pathways, in terms of the PAH world hypothesis, in producing precursors to biochemicals related to life as we know it.
Sources: en.wikipedia.org
=== Bandwidth === DisplayPort 1.2 has more bandwidth at 21.6 Gbit/s (17.28 Gbit/s plus overhead) as opposed to HDMI 2.0's 18 Gbit/s (14.4 Gbit/s plus overhead). DisplayPort 1.3 increased the bandwidth to 32.4 Gbit/s (25.92 Gbit/s plus overhead). HDMI 2.1 matched that by increasing the bandwidth up to 48 Gbit/s (42.67 Gbit/s plus overhead), adding an additional TMDS link in place of clock lane. In 2019, DisplayPort 2.0 once again achieved the bandwidth superiority of 80.0 Gbit/s. DisplayPort can also share bandwidth through the use of the Multi-Stream Transport (MST), which enables a single DP port to carry signals of several devices, to be demultiplexed at a branch hub.
== Side effects == Side effects of methenamine are minor and infrequent, reportedly occurring in fewer than 4% of individuals. They include dyspepsia (upset stomach), abdominal pain, dysuria (painful or uncomfortable urination), nausea, vomiting, diarrhea, headache, rash, and pruritus (itching). The drug is generally very well-tolerated. Rarely, reversibly elevated liver enzymes, including of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), have been reported. Normalization of liver enzymes has occurred with discontinuation or continuation of methenamine. Hypersensitivity reactions have also rarely been reported. It has been said that methenamine, overall, is very safe. Formaldehyde is a known carcinogen, for instance being associated with nasopharyngeal cancer and leukemia. This compound also occurs in small amounts as a contaminant in alcoholic beverages, and is chemically similar to the carcinogenic ethanol (alcohol) metabolite acetaldehyde. Because of the formaldehyde exposure with methenamine, there have been concerns about methenamine's potential carcinogenicity and the possibility that it might increase the risk of cancer, for instance bladder or stomach cancer. No clinical studies have looked directly at the long-term effects of methenamine in this regard. However, there are no published case reports documenting incidence of cancer with methenamine as of 2023. Moreover, animal studies have found no evidence of long-term carcinogenicity with oral methenamine.
=== Ethnicity and socioeconomic status === The rates of breastfeeding in the African-American community remain much lower than those of any other race, for a variety of proposed reasons. These include the legacy of wet nursing during slavery, higher rates of poor perinatal health, higher stress levels, less access to support, and less flexibility in the workplace. While for other races, as socio-economic status increases, rates of breastfeeding also go up, for the African-American community, breastfeeding rates remain consistently low regardless of socio-economic class. There are also racial disparities in access to maternity care practices that support breastfeeding. In the US, primarily African-American neighborhoods are more likely to have facilities (such as hospitals and female healthcare clinics) that do not support breastfeeding, contributing to the low rate of breastfeeding in the African-American community. Comparing facilities in primarily African American neighborhoods to ones in primarily European-American neighborhoods, the rates of practices that support or discourage breastfeeding were: limited use of supplements (13.1% compared with 25.8%) and rooming-in (27.7–39.4%) Low-income mothers are more likely to have unintended pregnancies. Mothers whose pregnancies are unintended are less likely to breastfeed. Especially the combination of powdered formula with unclean water can be very harmful to the health of babies. In the late 1970s, there was a boycott against Nestle due to the large number of baby deaths due to formula. Dr.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.